Wantai Bio subsidiary qualifies for national HPV vaccine procurement

Beijing Wantai Biological Pharmacy Enterprise's wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology, has successfully qualified for the 2025 National Immunization Program Vaccine Centralized Procurement project for its bivalent human papillomavirus (HPV) vaccine. The vaccine, which prevents diseases caused by high-risk HPV types 16 and 18, including cervical cancer, was accepted at a unit price of yuan 27.5.

This qualification is expected to expand the sales volume and market share of Wantai Bio's bivalent HPV vaccine within the domestic market. The company noted that as of the announcement date, global sales of its bivalent HPV vaccine have reached approximately 80m doses, contributing to the nation's efforts to eliminate cervical cancer.

The company cautioned that the final outcome, including procurement contracts, production, supply, and actual inoculation volumes, remains subject to uncertainty. Despite potential market pressures from imported and domestic nine-valent HPV vaccines, this entry into centralized procurement is anticipated to boost the company's brand influence.